Drug Index


Mechanism :

Cytarabine is a cell cycle phase-specific antineoplastic agent, affecting cells only during the S-phase of cell division. Intracellularly, cytarabine is converted into cytarabine-5-triphosphate, which is the active metabolite. The mechanism of action is not completely understood, but it appears that Ara-CTP acts primarily through inhibition of DNA polymerase.

Indication :

  • Acute lymphoblastic leukemia
  • Acute myeloid leukemia
  • Non-Hodgkin’s lymphoma

Contraindications :

Known hypersensitivity to the drug is a contraindication to its use.

Since Cytarabine is a potent bone marrow suppressant, it should be used cautiously in patients with pre-existing drug-induced bone marrow suppression, impaired liver function. Cytarabine may induce hyperuricemia due to rapid lysis of neoplastic cells.

Dosing :

IV 100-200 mg/m²/24 hours for 5-10 days or until remission followed by maintenance doses of 70-200 mg/m²/24 hours for 2-5 days/month.
Meningeal leukemia:
30 mg/m² intrathecally for 4 days.

Adverse Effect :

Quadriplegia and paralysis with intrathecal administration. Myelosuppression (megaloblastosis, reticulocytopenia, thrombocytopenia and anemia), nausea, vomiting, diarrhea, anorexia, oral and anal ulceration, sore throat, esophagitis, oesophageal ulceration and gastrointestinal haemorrhage, fever, rash, alopecia, skin ulceration, conjunctivitis, chest pain, urinary retention, dizziness, neuritis, cellulitis or thrombophlebitis at the site of injection.

Cytarabine reaction: Cytarabine syndrome/reaction is characterized by fever, myalgia, bone pain, occasionally chest pain, maculopapular rash, conjunctivitis and malaise. It usually occurs 6-12 hours after administration.

Interaction :

Digoxin: Absorption of oral digoxin may be substantially reduced.
Gentamicin, Flucytosine: Cytarabine may antagonize activity.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50100% of conventional low dose regime. For high dose,
10-20100% of conventional low dose regime. For high dose,
<10100% of conventional low dose regime. For high dose,

Dose in Patients undergoing Renal Replacement Therapies
CAPDNot dialysed. Dose as in GFR<10 mL/min
HDNot dialysed. Dose as in GFR<10 mL/min
HDF/High fluxDialysed. Dose as in GFR<10 mL/ min
CAV/VVHDUnknown dialysability. Dose as in GFR=10–20 mL/min

Hepatic Dose :

Use with caution. Adjust dose as per clinical response.
02/20/2024 23:52:45 Cytarabine
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0